Cancer feature: cnaPANCAN411

ABHD2 ACAN ADAMTS17 AEN ALDH1A3 ANPEP AP3S2 ARRDC4 ASB7 BLM C15orf32 C15orf38 C15orf38-AP3S2 CERS3 CHD2 CHSY1 CIB1 CRTC3 CTD-2054N24.2 DET1 FAM169B FAM174B FANCI FES FURIN GDPGP1 HAPLN3 HDDC3 IDH2 IGF1R IQGAP1 ISG20 KIF7 LINC00923 LINS LRRC28 LRRK1 LYSMD4 MAN2A2 MCTP2 MEF2A MESP1 MESP2 MFGE8 MRPL46 MRPS11 NGRN NR2F2 NTRK3 PCSK6 PEX11A PGPEP1L PLIN1 POLG PRC1 RCCD1 RGMA RHCG RLBP1 RP11-697E2.6 SEMA4B SLCO3A1 SNRPA1 SPATA8 ST8SIA2 SV2B SYNM TICRR TTC23 TTLL13 UNC45A VIMP VPS33B WDR93 ZNF710 ZNF774

Known Driver Genes: BLM,IDH2

Copy number alternation: gain

Linsitinib

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer